Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, et al. J Clin Oncol 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124.

Read + Share

Amedeo Smart

Independent Medical Education

Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124.
PMID: 39671533